rofecoxib has been researched along with Curling Ulcer in 8 studies
Curling Ulcer: Acute stress DUODENAL ULCER, usually observed in patients with extensive third-degree burns.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We hypothesized that COX-2-specific inhibition with rofecoxib (25 mg once daily) in the treatment of patients with osteoarthritis would cause fewer gastroduodenal ulcers than an equally effective dose of ibuprofen (800 mg 3 times a day), a nonspecific COX inhibitor." | 9.09 | A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Rofecoxib Osteoarthritis Endoscopy Study Group. ( Bath, R; Bolognese, J; Harper, S; Johanson, J; Laine, L; Quan, H; Schwartz, H; Simon, T; Stern, S, 1999) |
| " We hypothesized that COX-2-specific inhibition with rofecoxib (25 mg once daily) in the treatment of patients with osteoarthritis would cause fewer gastroduodenal ulcers than an equally effective dose of ibuprofen (800 mg 3 times a day), a nonspecific COX inhibitor." | 5.09 | A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Rofecoxib Osteoarthritis Endoscopy Study Group. ( Bath, R; Bolognese, J; Harper, S; Johanson, J; Laine, L; Quan, H; Schwartz, H; Simon, T; Stern, S, 1999) |
| "This randomized, double-blind study tested the hypothesis that rofecoxib, a drug that specifically inhibits cyclooxygenase 2, would cause fewer gastroduodenal ulcers than ibuprofen (in a multicenter trial), and its side effects would be equivalent to those of placebo (in a prespecified analysis combining the results with another trial of identical design)." | 5.09 | Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis: a randomized, double-blind, placebo-controlled trial. The Rofecoxib Osteoarthritis Endoscopy Multina ( Acevedo, E; Beaulieu, A; Bolognese, J; Hawkey, C; Laine, L; Maldonado-Cocco, J; Mortensen, E; Quan, H; Shahane, A; Simon, T, 2000) |
| "To update the results of a previously performed analysis of the incidence of upper GI perforations, symptomatic gastroduodenal ulcers, and upper GI bleeding (PUBs) with rofecoxib compared with non-selective NSAIDs." | 4.82 | The upper gastrointestinal safety of rofecoxib vs. NSAIDs: an updated combined analysis. ( Bolognese, JA; Reicin, AS; Simon, TJ; Watson, DJ; Yu, Q, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (25.00) | 18.2507 |
| 2000's | 6 (75.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Araki, H | 1 |
| Komoike, Y | 1 |
| Matsumoto, M | 1 |
| Tanaka, A | 1 |
| Takeuchi, K | 1 |
| Watson, DJ | 1 |
| Yu, Q | 1 |
| Bolognese, JA | 2 |
| Reicin, AS | 1 |
| Simon, TJ | 2 |
| Lima RodrÃguez, EM | 1 |
| Calvo Romero, JM | 1 |
| Lanza, FL | 1 |
| Rack, MF | 1 |
| Quan, H | 3 |
| Hoover, ME | 1 |
| Wilson, FR | 1 |
| Harper, SE | 1 |
| Laine, L | 2 |
| Harper, S | 1 |
| Simon, T | 2 |
| Bath, R | 1 |
| Johanson, J | 1 |
| Schwartz, H | 1 |
| Stern, S | 1 |
| Bolognese, J | 2 |
| Hawkey, C | 1 |
| Beaulieu, A | 1 |
| Maldonado-Cocco, J | 1 |
| Acevedo, E | 1 |
| Shahane, A | 1 |
| Mortensen, E | 1 |
| Noble, SL | 1 |
| King, DS | 1 |
| Olutade, JI | 1 |
| Bannwarth, B | 1 |
3 reviews available for rofecoxib and Curling Ulcer
| Article | Year |
|---|---|
The upper gastrointestinal safety of rofecoxib vs. NSAIDs: an updated combined analysis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase Inhibitors; Double-Blind Method; Duodenal Ul | 2004 |
Cyclooxygenase-2 enzyme inhibitors: place in therapy.
Topics: Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Bleeding Time; Blood P | 2000 |
[COX-2 specific inhibitors: are NSAIDs and the stomach become reconcilied?].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; C | 2001 |
3 trials available for rofecoxib and Curling Ulcer
2 other studies available for rofecoxib and Curling Ulcer
| Article | Year |
|---|---|
Healing of duodenal ulcers is not impaired by indomethacin or rofecoxib, the selective COX-2 inhibitor, in rats.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase Inhibitors; Duodenal Ulcer; Enzyme | 2002 |
[Gastro-intestinal toxicity of rofecoxib].
Topics: Aged; Cyclooxygenase Inhibitors; Drug-Related Side Effects and Adverse Reactions; Duodenal Ulcer; Fe | 2005 |